{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:33:38Z","timestamp":1768916018343,"version":"3.49.0"},"reference-count":24,"publisher":"BMJ","issue":"15","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,12,20]]},"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess stroke\/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>There were 14\u2009793 patients with known VHD status, categorised as having moderate or severe mitral regurgitation (MR) (n=3382), aortic regurgitation (AR) (n=842) or aortic stenosis (AS) (n=324); patients with moderate or severe mitral stenosis were excluded from the trial. Baseline characteristics, efficacy and safety outcomes were compared between each type and no significant VHD. Treatment effect was assessed using an adjusted model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients with MR or AR had similar rates of stroke\/systemic embolism and bleeding compared with patients without MR or AR, respectively. Patients with AS had significantly higher event rates (presented as rate per 100 patient-years of follow-up) of stroke\/systemic embolism (3.47 vs 1.36; adjusted HR (adjHR) 2.21, 95%\u2009CI 1.35 to 3.63), death (8.30 vs 3.53; adjHR 1.92, 95%\u2009CI 1.41 to 2.61), major bleeding (5.31 vs 2.53; adjHR 1.80, 95%\u2009CI 1.19 to 2.75) and intracranial bleeding (1.29 vs 0.51; adjHR 2.54, 95%\u2009CI 1.08 to 5.96) than patients without AS. The superiority of apixaban over warfarin on stroke\/systemic embolism was similar in patients with versus without MR (HR 0.69, 95%\u2009CI 0.46 to 1.04 vs HR 0.79, 95%\u2009CI 0.63 to 1.00; interaction P value 0.52), with versus without AR (HR 0.57, 95%\u2009CI 0.27 to 1.20 vs HR 0.78, 95% CI 0.63 to 0.96; interaction P value 0.52), and with versus without AS (HR 0.44, 95%\u2009CI 0.17 to 1.13 vs HR 0.79, 95%\u2009CI 0.64 to 0.97; interaction P value 0.19). For each of the primary and secondary efficacy and safety outcomes, there was no evidence of a different effect of apixaban over warfarin in patients with any VHD subcategory.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In anticoagulated patients with AF, AS is associated with a higher risk of stroke\/systemic embolism, bleeding and death. The efficacy and safety benefits of apixaban compared with warfarin were consistent, regardless of presence of MR, AR or AS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial registration<\/jats:title>\n                  <jats:p>ARISTOTLE clinical trial number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00412984\">NCT00412984<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2017-312272","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T12:15:21Z","timestamp":1516364121000},"page":"1292-1299","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease"],"prefix":"10.1136","volume":"104","clinical-trial-number":[{"clinical-trial-number":"nct00412984","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dragos","family":"Vinereanu","sequence":"first","affiliation":[{"name":"Cardiology, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania"},{"name":"Cardiology, University and Emergency Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Mulder","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Jansky","sequence":"additional","affiliation":[{"name":"University Hospital Motol, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[{"name":"Lady Davis Carmel Medical Center, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J","family":"Gersh","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Avezum","sequence":"additional","affiliation":[{"name":"Dante Pazzanese Institute, S\u00e3o Paulo University, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H","family":"Alexander","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"2025091921545432000_104.15.1292.1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.11.2628"},{"key":"2025091921545432000_104.15.1292.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu352"},{"key":"2025091921545432000_104.15.1292.3","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/clc.20433","article-title":"Effect of mitral regurgitation on cerebrovascular accidents in patients with atrial fibrillation and left atrial thrombus","volume":"32","author":"Nair","year":"2009","journal-title":"Clin Cardiol"},{"key":"2025091921545432000_104.15.1292.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70231-5"},{"key":"2025091921545432000_104.15.1292.5","doi-asserted-by":"crossref","first-page":"1822.2","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with \u2019non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project","volume":"36","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"2025091921545432000_104.15.1292.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025091921545432000_104.15.1292.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014807"},{"key":"2025091921545432000_104.15.1292.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.07.035"},{"key":"2025091921545432000_104.15.1292.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020950"},{"key":"2025091921545432000_104.15.1292.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu305"},{"key":"2025091921545432000_104.15.1292.11","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308120"},{"key":"2025091921545432000_104.15.1292.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2009.06.051"},{"key":"2025091921545432000_104.15.1292.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00208-9"},{"key":"2025091921545432000_104.15.1292.14","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/jth.12734","article-title":"Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation","volume":"12","author":"Blackshear","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2025091921545432000_104.15.1292.15","doi-asserted-by":"publisher","DOI":"10.1177\/1076029616648407"},{"key":"2025091921545432000_104.15.1292.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.01.389"},{"key":"2025091921545432000_104.15.1292.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2015.06.002"},{"key":"2025091921545432000_104.15.1292.18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.01.016","article-title":"Increased bleeding risk in patients with aortic valvular stenosis: From new mechanisms to new therapies","volume":"139","author":"Natorska","year":"2016","journal-title":"Thromb Res"},{"key":"2025091921545432000_104.15.1292.19","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.217273"},{"key":"2025091921545432000_104.15.1292.20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MAT.0b013e31824363e7","article-title":"shear stress, and ADAMTS13 in hemostasis and thrombosis","volume":"58","author":"Tsai","year":"2012","journal-title":"ASAIO J"},{"key":"2025091921545432000_104.15.1292.21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.11.1290"},{"key":"2025091921545432000_104.15.1292.22","first-page":"e199","article-title":"AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"2014","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2025091921545432000_104.15.1292.23","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"2016","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2025091921545432000_104.15.1292.24","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu178"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-312272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:55:02Z","timestamp":1758344102000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-312272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":24,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2018,7,12]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/heartjnl-2017-312272"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-312272","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]}}}